DK1003546T3 - Fremgangsmåde til behandling af patienter ramt af dissemineret sklerose ved anvendelse af konsensus interferon - Google Patents

Fremgangsmåde til behandling af patienter ramt af dissemineret sklerose ved anvendelse af konsensus interferon

Info

Publication number
DK1003546T3
DK1003546T3 DK98933344T DK98933344T DK1003546T3 DK 1003546 T3 DK1003546 T3 DK 1003546T3 DK 98933344 T DK98933344 T DK 98933344T DK 98933344 T DK98933344 T DK 98933344T DK 1003546 T3 DK1003546 T3 DK 1003546T3
Authority
DK
Denmark
Prior art keywords
treating patients
patients affected
consensus interferon
disseminated sclerosis
sclerosis
Prior art date
Application number
DK98933344T
Other languages
English (en)
Inventor
David Martin
Norman L Fischer
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of DK1003546T3 publication Critical patent/DK1003546T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK98933344T 1997-08-15 1998-07-15 Fremgangsmåde til behandling af patienter ramt af dissemineret sklerose ved anvendelse af konsensus interferon DK1003546T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/911,893 US6013253A (en) 1997-08-15 1997-08-15 Treatment of multiple sclerosis using consensus interferon and IL-1 receptor antagonist

Publications (1)

Publication Number Publication Date
DK1003546T3 true DK1003546T3 (da) 2006-10-30

Family

ID=25431058

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98933344T DK1003546T3 (da) 1997-08-15 1998-07-15 Fremgangsmåde til behandling af patienter ramt af dissemineret sklerose ved anvendelse af konsensus interferon

Country Status (17)

Country Link
US (1) US6013253A (da)
EP (1) EP1003546B1 (da)
JP (1) JP3813440B2 (da)
KR (1) KR100415636B1 (da)
CN (1) CN1183963C (da)
AT (1) ATE338563T1 (da)
AU (1) AU741074B2 (da)
CA (1) CA2299361C (da)
CY (1) CY1107314T1 (da)
DE (1) DE69835823T2 (da)
DK (1) DK1003546T3 (da)
ES (1) ES2267188T3 (da)
HU (1) HU229045B1 (da)
IL (2) IL134345A0 (da)
PT (1) PT1003546E (da)
TW (1) TW474817B (da)
WO (1) WO1999008702A1 (da)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6982089B2 (en) 1999-02-24 2006-01-03 Tact Ip, Llc Cytokine antagonists for neurological and neuropsychiatric disorders
US6471961B1 (en) * 1999-02-24 2002-10-29 Edward L. Tobinick Interleukin antagonists for the treatment of neurological, retinal and muscular disorders
US20030007972A1 (en) * 1999-02-24 2003-01-09 Edward Tobinick Cytokine antagonists and other biologics for the treatment of bone metastases
US7214658B2 (en) * 2004-07-06 2007-05-08 Tact Ip, Llc Method of delivering a TNF antagonist to the brain of a human by perispinal administration without direct intrathecal injection
US6623736B2 (en) * 2000-05-02 2003-09-23 Edward L. Tobinick Interleukin antagonists for the treatment of neurological, retinal and muscular disorders
AU2002246619A1 (en) * 2000-12-08 2003-06-23 Neuronz Limited Use of insuline-like growth factor-i for promoting remyelination of axons
US7714020B2 (en) 2001-05-24 2010-05-11 Neuren Pharmaceuticals Limited Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate
ATE435852T1 (de) 2001-05-24 2009-07-15 Neuren Pharmaceuticals Ltd Gpe-analoga und peptidomimetika
US7605177B2 (en) 2001-05-24 2009-10-20 Neuren Pharmaceuticals Limited Effects of glycyl-2 methyl prolyl glutamate on neurodegeneration
US7230167B2 (en) 2001-08-31 2007-06-12 Syngenta Participations Ag Modified Cry3A toxins and nucleic acid sequences coding therefor
PT1471974E (pt) * 2002-02-06 2007-10-12 Ares Trading Sa Factor de necrose tumural combinado com interferão em doenças desmielinizantes
EP3064215A1 (en) * 2002-10-16 2016-09-07 Samuel F. Hunter Method for treatment of demyelinating central nervous system disease
TWI272948B (en) 2003-05-01 2007-02-11 Ares Trading Sa HSA-free stabilized interferon liquid formulations
CN103755800B (zh) 2004-02-02 2016-02-24 Ambrx公司 经修饰的人类生长激素多肽与其用途
DE102004008168B4 (de) * 2004-02-19 2015-12-10 Voxeljet Ag Verfahren und Vorrichtung zum Auftragen von Fluiden und Verwendung der Vorrichtung
UA88300C2 (ru) * 2004-05-17 2009-10-12 Эйрес Трейдинг С.А. Гидрогелевые композиции, которые содержат интерферон
EA010979B1 (ru) 2004-06-01 2008-12-30 Арес Трейдинг С.А. Стабилизированные жидкие препаративные формы интерферона
MXPA06014079A (es) 2004-06-01 2007-02-15 Ares Trading Sa Metodo para estabilizar proteinas.
TW200633718A (en) * 2004-12-16 2006-10-01 Applied Research Systems Treatment of hepatitis c in the asian population
BG66458B1 (bg) 2005-03-21 2014-10-31 Иван Иванов Средство за конкурентно инхибиране на ендогенен гама интерферон
US20100028296A1 (en) * 2005-05-02 2010-02-04 Chavez Raymond A Use of cytokine-derived peptides in treatment of pain and neurodegenerative disease
DK1917276T3 (da) 2005-08-26 2018-05-07 Ares Trading Sa Fremgangsmåde til fremstilling af glycosyleret Interferon Beta
JP2009507003A (ja) * 2005-09-01 2009-02-19 アレス トレーディング ソシエテ アノニム 視神経炎の治療
CA2649810A1 (en) 2006-05-24 2007-11-29 Laboratoires Serono S.A. Cladribine regimen for treating multiple sclerosis
BRPI0821029A2 (pt) * 2007-12-20 2015-06-16 Merck Serono Sa Fomulações de peg-interferon-beta
BG66517B1 (bg) 2008-04-08 2016-02-29 Tigo Gmbh Супресор на ендогенния човешки гама - интерферон
US9359421B2 (en) 2008-04-08 2016-06-07 Tigo Gmbh Suppressor of the endogenous interferon-gamma
US20130017999A1 (en) 2011-07-14 2013-01-17 Marc Fremont Methods and Compositions for Evaluating and/or Treating Chronic Immune Diseases
DK3369435T3 (da) 2013-07-18 2019-11-25 Xalud Therapeutics Inc Sammensætning til behandling af inflammatorisk ledsygdom
BG67190B1 (bg) 2017-03-29 2020-11-16 Tigo Gmbh Анти-гама мутантен протеин срещу ендогенния човешки гама интерферон
CN119097635A (zh) 2017-11-24 2024-12-10 默克专利股份公司 用于治疗进展型形式的多发性硬化症的克拉屈滨疗法
US20240226284A1 (en) 2020-09-10 2024-07-11 Merck Patent Gmbh Novel treatment regimen for the treatment of autoimmune disorders

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936694B1 (en) * 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US5075222A (en) * 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
HUT64582A (en) * 1989-11-29 1994-01-28 Synergen Inc Method for producing recombinant human interleukin-1 inhibitor
AU7683391A (en) * 1990-04-27 1991-11-27 Upjohn Company, The Modified interleukin-1 inhibitors
US5372808A (en) * 1990-10-17 1994-12-13 Amgen Inc. Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
WO1992006707A1 (en) * 1990-10-17 1992-04-30 Amgen Inc. Methods and compositions for the treatment of cell proliferation disorders
US5858355A (en) * 1990-12-20 1999-01-12 University Of Pittsburgh Of The Commonwealth System Of Higher Education IRAP gene as treatment for arthritis
GEP20033082B (en) * 1991-03-15 2003-10-27 Amgen Inc Pegylation of Polypeptides
EP0639079B1 (en) * 1992-04-30 2000-01-12 Amgen Inc. Methods for treating interleukin-1 and tumor necrosis factor mediated diseases
CZ291261B6 (cs) * 1992-09-17 2003-01-15 Amgen Inc. Farmaceutická kompozice pro léčení nemocí zprostředkovaných interleukinem-1
US5780021A (en) * 1993-03-05 1998-07-14 Georgetown University Method for treating type 1 diabetes using α-interferon and/or β-i
JPH08511507A (ja) * 1993-03-08 1996-12-03 ユニバーシティー オブ ピッツバーグ オブ ザ コモンウェルス システム オブ ハイヤー エデュケーション 哺乳動物宿主の結合組織を処置するための遺伝子導入
WO1994021275A1 (fr) * 1993-03-19 1994-09-29 Vacsyn S.A. Compositions pour l'application en therapeutique humaine, caracterisees par l'association d'un muramyl-peptide a une cytokine
US6326353B1 (en) * 1993-03-23 2001-12-04 Sequus Pharmaceuticals, Inc. Enhanced circulation effector composition and method
FR2706772A1 (en) * 1993-06-22 1994-12-30 Vacsyn Sa Prevention and treatment of septic syndrome with an immunosuppressant, in particular cyclosporin.
DE69521880T2 (de) * 1994-02-08 2002-01-03 Amgen Inc., Thousand Oaks Orales verabreichungssystem von chemischmodifizierten proteinen g-csf

Also Published As

Publication number Publication date
HUP0002755A3 (en) 2001-11-28
KR100415636B1 (ko) 2004-01-24
ATE338563T1 (de) 2006-09-15
AU741074B2 (en) 2001-11-22
KR20010030563A (ko) 2001-04-16
AU8300698A (en) 1999-03-08
US6013253A (en) 2000-01-11
EP1003546A1 (en) 2000-05-31
CA2299361C (en) 2009-09-29
JP3813440B2 (ja) 2006-08-23
JP2001515047A (ja) 2001-09-18
EP1003546B1 (en) 2006-09-06
IL134345A0 (en) 2001-04-30
CA2299361A1 (en) 1999-02-25
CN1267225A (zh) 2000-09-20
CY1107314T1 (el) 2012-11-21
TW474817B (en) 2002-02-01
ES2267188T3 (es) 2007-03-01
CN1183963C (zh) 2005-01-12
PT1003546E (pt) 2006-12-29
HUP0002755A2 (hu) 2000-12-28
DE69835823T2 (de) 2007-08-09
DE69835823D1 (de) 2006-10-19
HU229045B1 (en) 2013-07-29
IL134345A (en) 2011-03-31
WO1999008702A1 (en) 1999-02-25
HK1030157A1 (en) 2001-04-27

Similar Documents

Publication Publication Date Title
ATE338563T1 (de) Verfahren zur behandlung von patienten die unter multipler sklerose leiden mit konsensus- interferon
NO965378D0 (no) Pyrazolo- og pyrolopyridiner
DK0911033T3 (da) Anvendelse af konsensusinterferon til reduktion af bivirkningerne af interferonbehandling i viral hepatitis
DK0713701T3 (da) 2-Brommelatonin til behandling af søvnforstyrrelser
FI950465L (fi) Läpäisevä laastari lääkityksen antamiseksi ihoon
PT966447E (pt) Moleculas pequenas uteis no tratamento de doencas inflamatorias
DK0880350T3 (da) Behandling af dissemineret sklerose
DK0973735T3 (da) Polyaromatiske antivirale præparater
DK0914144T3 (da) Terapeutiske anvendelser af BPI-protein-produkter til human meningokokæmi
EE9900036A (et) Uued ühendid ja kompositsioonid trüptaasi aktiivsusega seotud haiguste raviks
DK19893D0 (da) Praeparat til nasal behandling
IL161889A0 (en) Method for treating diseases with omega interferon
EE9900477A (et) Ühendid ja kompositsioonid seriinproteaasse, eriti trüptaasse aktiivsusega seotud haiguste raviks
DK1082131T3 (da) Immunoregulator
DK0817646T3 (da) Fremgangsmåder til behandling af inflammation og præparater derfor
EA199800717A1 (ru) Способ лечения заболеваний млекопитающих и цвиттерионная композиция
PT900563E (pt) Producao de formulacoes farmaceuticas para o tratamento de edema e doencas venosas
DK1007040T3 (da) Anvendelsen af phanquinon til behandlingen af Alzheimers sygdom
LV10191A (lv) Farmaceitiski lidzekli hepatita B virusa izraisito infekciju un slimibu arstesanai
DK0752884T3 (da) Fremgangsmåde til behandling af auto-immune sygdomme ved anvendelse af type 1 interferoner
DK0862454T3 (da) CTLA-8 i kombination med G-CSF eller med G-CSF og IL-6 og anvendelse af CTLA-8 til behandling af infektioner
NO20005548L (no) Mykobakterieinhibitorer
ATE270113T1 (de) Zusammenstellungen zur verbesserten wundheilung
DK1019032T3 (da) Fremgangsmåde til at forhindre misbrug af et transdermalt terapeutisk system
EA200300222A1 (ru) Лечение гепатита c с помощью тимозина, интерферона и рибавирина